Last reviewed · How we verify

Faculdade de Ciências Médicas da Santa Casa de São Paulo — Portfolio Competitive Intelligence Brief

Faculdade de Ciências Médicas da Santa Casa de São Paulo pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
sugammadex ED90 sugammadex ED90 marketed Selective relaxant binding agent Rocuronium and vecuronium (steroidal neuromuscular blocking agents) Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Korea University Guro Hospital · 1 shared drug class
  2. Merck Sharp & Dohme LLC · 1 shared drug class
  3. Regina Elena Cancer Institute · 1 shared drug class
  4. University Health Network, Toronto · 1 shared drug class
  5. University of California, Irvine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Faculdade de Ciências Médicas da Santa Casa de São Paulo:

Cite this brief

Drug Landscape (2026). Faculdade de Ciências Médicas da Santa Casa de São Paulo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/faculdade-de-ci-ncias-m-dicas-da-santa-casa-de-s-o-paulo. Accessed 2026-05-18.

Related